Identifying “at-risk” patients for sub-optimal beta-lactam exposure in critically ill patients with severe infections

Схожие документы

• Continuous beta-lactam infusion in critically ill patients: the clinical evidence
  по: Abdul-Aziz, Mohd H, и др.
  Опубликовано: (2012)
• Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review
  по: Sime, Fekade Bruck, и др.
  Опубликовано: (2012)
• Beta-lactam antibiotics in continuous infusion in critically ill patients
  по: Jeurissen, Axel, и др.
  Опубликовано: (2010)
• We need to optimize piperacillin-tazobactam dosing in critically ill patients—but how?
  по: Cotta, Menino Osbert, и др.
  Опубликовано: (2016)
• Provider perspectives on beta-lactam therapeutic drug monitoring programs in the critically ill: a protocol for a multicenter mixed-methods study
  по: Barreto, Erin F., и др.
  Опубликовано: (2021)